When GSK (then Glaxo Laboratories) introduced the infant formula milk brand Farex in India way back in 1924, it was the nutritional needs of infants that drove the decision. The baby food brand, which has long since changed hands, went on to become a household name in the country.
Building On 100 Years In India: The Next Big Things On GSK’s Horizon
GSK’s India chief talks to Scrip about new category creation in adult immunization with Shingrix seeing strong uptake, Nucala and Trelegy’s trajectory and oncology assets set for debut as the company steps into its 100th year of operation in the country. GSK expects to continue to transform its operating model as things evolve, he indicates in the concluding part of this interview.
More from Business
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
More from Interviews
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
The founder and CEO of Ultragenyx talked with Scrip as the company approaches a pivotal data readout and awaits US FDA action on its first gene therapy.
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.